Drug intelligence / Profile preview

phyllanthus niruri + boerhaavia diffusa + picrorhiza kurroa

Development stage
Preclinical
Administration
Oral
01

Overview

This is a combination herbal preparation comprising **phyllanthus niruri**, **boerhaavia diffusa**, and **picrorhiza kurroa**—three botanicals widely used in Ayurvedic and traditional medicines for hepatoprotective, nephroprotective, immunomodulatory, anti-inflammatory, and antioxidant properties. - **Phyllanthus niruri**: Traditionally used for **urinary tract health** (antiurolithic), hepatoprotection, and relief in digestive disorders. Its mechanism involves inhibition of stone formation via modulation of calcium oxalate crystallization, antioxidative action, and mild diuretic effect. Some data suggest immunomodulatory and mild antimicrobial effects, but evidence remains limited[3]. - **Boerhaavia diffusa**: Used as a **diuretic, hepatoprotective, anti-inflammatory, and immunomodulatory** agent. Its bioactives (notably boeravinone compounds and punarnavine alkaloids) modulate cellular signaling (inhibition of NF-κB), enhance renal blood flow, provide antioxidant and anti-inflammatory effects, and regulate immune cell function, both stimulating and suppressing various immune cells depending on context[1]. - **Picrorhiza kurroa**: Extensively used for **liver disorders, inflammation, and immune regulation**. Rich in iridoid glycosides (especially kutkin, picrosides), it exerts **hepatoprotective, anti-inflammatory (modulating NF-κB), antioxidant, antidiabetic, and immunomodulatory** effects. It inhibits pro-inflammatory cytokines and is used in traditional medicine for digestive, hepatic, and some autoimmune conditions[2][4]. This **polyherbal combination** is generally formulated for comprehensive liver support, nephroprotection, or immunomodulation, but scientific evidence for synergistic efficacy and safety is limited. The combination works via multi-target effects: antioxidant activity, modulation of pro- and anti-inflammatory cytokines (such as TNF-α, IL-1β, IL-10), enhancement of cellular immune response, inhibition of inflammatory signaling (primarily NF-κB), and improved regeneration/repair mechanisms in hepatic and renal cells[1][2].

02

Targets

MIF (Oxidized macrophage migration inhibitory factor)AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)

Beyond the preview

Go deeper on phyllanthus niruri + boerhaavia diffusa + picrorhiza kurroa.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on phyllanthus niruri + boerhaavia diffusa + picrorhiza kurroa.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call